RT Journal Article
SR Electronic
T1 Angioedema, ACE inhibitor and COVID-19
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e237888
DO 10.1136/bcr-2020-237888
VO 13
IS 9
A1 Ekjot Grewal
A1 Bayu Sutarjono
A1 Ibbad Mohammed
YR 2020
UL http://casereports.bmj.com/content/13/9/e237888.abstract
AB SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. Finally, we also describe possible pathways that exist for SARS-CoV-2 to interact with the mechanism behind angioedema.